drugset

drugset / Trial / NCT00658970

Evaluation of KX2-391 in Patients With Advanced Malignancies

NCT00658970 ↗

Phase 1 Completed 50 enrolled Athenex, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.

Timeline

Start: 2007-11
Primary completion: 2010-03
Completion: 2011-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirbanibulin	Small molecule	2 mg	Oral

Indications